A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.

119th Congress Introduced by Angela Alsobrooks and 3 co-sponsors

The bill would streamline FDA biosimilar review under the Public Health Service Act, potentially shortening timelines and easing regulatory hurdles for approval.

Introduced in Senate

Summary of Bill: S.5059 (119th Congress)

Purpose

S.5059 aims to amend the Public Health Service Act with the goal of streamlining the FDA review process for biosimilar biological products. The bill seeks to simplify certain statutory review requirements to expedite the assessment and potential approval of biosimilars.

Key Provisions and Changes

Amends Section 351(k)(5) of the Public Health Service Act (42 U.S.C. 262(k)(5)).

Specific changes:

Subparagraph (B) of Section 351(k)(5) is struck.
Subparagraph (C) is redesignated as subparagraph (B).

Note: The text provided does not include the full revised language or the precise operational effects of substituting or relettering the subsections. The effect, in principle, is to modify the review framework under which biosimilar products are evaluated, potentially altering benchmarks, processes, or criteria within the FDA’s biosimilar review pathway.

Who Is Affected

Biosimilar biological product sponsors seeking FDA review and potential approval.

The FDA, as the agency charged with administering and overseeing biosimilar approvals under the Public Health Service Act.

Manufacturers and developers of biosimilars who rely on a streamlined process for regulatory review.

Potential Impacts

Administrative: Changes to the statutory subsections governing biosimilar review could alter timelines, documentation requirements, or review milestones.

Regulatory: By streamlining review, the bill may shorten approval timelines or reduce procedural hurdles, potentially accelerating access to biosimilar medicines.

Market: Faster approvals could increase competition in the biosimilar market, potentially affecting pricing and patient access to biosimilar options.

Procedural and Timeline Aspects

Status: Introduced in the Senate on July 21, 2026; referred to the Committee on Health, Education, Labor, and Pensions.

Next steps typically include committee consideration, potential markup, passage by chamber, and subsequent conference or floor votes, followed by enactment into law if approved by both houses and signed by the President.

The bill does not specify a effective date or enforcement timeline in the excerpt provided; such details may be addressed in the full text or subsequent legislative actions.

Notes

The available text is limited to a structural change within Section 351(k)(5) and does not present the full revised statutory language or the detailed regulatory consequences.

Sponsors include Senators Angela Alsobrooks, Rick Scott, Lisa Blunt Rochester, and Ashley Moody.

If you’d like, I can provide a more detailed analysis once the full legislative text is available, including how the relettering of subsections interacts with existing FDA review requirements and any defined timelines or criteria introduced by the amendment.